Botulinum toxin in psoriasis: A Review
International Journal of Development Research
Botulinum toxin in psoriasis: A Review
Received 03rd January, 2022; Received in revised form 20th February, 2022; Accepted 11th March, 2022; Published online 30th April, 2022
Copyright©2022, Mariana Moroti Vicari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Psoriasis is a chronic inflammatory disease involving the exacerbated production of keratinocytes in the affected areas, in response to the activation of the immune system. Some neurotransmitter channels are involved in the pathogenesis of psoriasis and may act as a trigger for the pathology. This article aims to demonstrate the use of Botulinum Toxin A as a substance capable of interfering in the immunopathogenesis of the disease.A bibliographic review was carried out using articles indexed in the MEDLINE AND LILACS platforms, in both English and Portuguese. Review articles were not included. Cutaneous nerves in lesions can activate the production of IL-23 by dermal dendritic cells, triggering the expression and release of interleukin (IL)-17 – the major inflammatory response factor – by T cells. Botulinum Toxin A, acts directly in this tract.Improvement reports show the applicability of botulinum toxin as a safe and practical treatment option for daily clinic practice.
